SUMO2P16

Across TCGA pan-cancer cohorts, SUMO2P16 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SUMO2P16’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SUMO2P16 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SUMO2P16 is over-expressed in tumor, although a few such as PAAD show the opposite, repressed pattern.

HNSC, PAAD, and UCEC are the cancer types where SUMO2P16 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SUMO2P16 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	II,III,IV	+0.083	.006	7	view →
PAAD	Female	All	−0.345	.044	2	view →
UCEC	All	All	+0.122	.033	2	view →
CHOL	All	All	+0.130	.023	1	view →
THCA	Male	All	+0.120	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SUMO2P16–HNSC

Open the HNSC breakdown →